Baxalta Inc. (NYSE: BXLT) is scheduled to report fourth-quarter and full-year results before markets open on Tuesday. The hematology and immunology focused biopharmaceutical company is expected to post earnings per share (EPS) of $0.56 and revenues of $1.71 billion for the quarter, as well as full-year EPS of $2.07 on revenues of $6.17 billion.

Baxalta, which was spun out of Baxter International Inc. (NYSE: BAX) last July, reported per-share earnings of $0.56 back in the third quarter, which handily exceeded analysts’ expectations. Guidance at the time called for EPS of $0.55 to $0.57 for the fourth quarter.

The big news for Baxalta is that last month it finally agreed to merge with U.K.-based Shire PLC (NASDAQ: SHPG) in a deal worth around $32 billion. Shire first made a bid for Baxalta on August 4, but Baxalta said that bid was too low. The deal now is expected to close in mid-2016.

Back in December of 2015, Baxalta announced it had received a key U.S. Food and Drug Administration (FDA) approval for its drug that treats von Willebrand disease, a rare inherited bleeding disorder that results from a missing protein. The company plans to launch the drug under the brand name Vonvendi, expanding its portfolio of treatments for bleeding disorders, led by the hemophilia treatments Advate and Feiba.

In November, Baxalta won FDA approval for Adynovate, a long-acting version of Advate poised to contend with a new therapy from Biogen and in-development products from Bayer and Novo Nordisk. Baxalta set a very ambitious goal of launching 20 new products by 2020, with the intent to grow its annual revenue to $8.5 billion in the process.

Shares of Baxalta closed most recently at $38.67, in a 52-week trading range of $29.83 to $42.38. The consensus price target is $46.50, yielding an implied upside of almost 17%.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.